Cargando…

Synthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α(1A)/α(1D)-Adrenergic Receptor Antagonist with Potential Uroselective Profile

Benign prostatic hyperplasia (BPH) is the most common male clinical problem impacting the quality of life of older men. Clinical studies have indicated that the inhibition of α(1A)-/α(1D) adrenoceptors might offer effective therapy in lower urinary tract symptoms. Herein, a limited series of arylsul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canale, Vittorio, Rak, Aleksandra, Kotańska, Magdalena, Knutelska, Joanna, Siwek, Agata, Bednarski, Marek, Nowiński, Leszek, Zygmunt, Małgorzata, Koczurkiewicz, Paulina, Pękala, Elżbieta, Sapa, Jacek, Zajdel, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225212/ https://www.ncbi.nlm.nih.gov/pubmed/30158432 http://dx.doi.org/10.3390/molecules23092175

Ejemplares similares

Focus on Silodosin: Pros and Cons of Uroselectivity
por: Califano, Gianluigi, et al.
Publicado: (2020)

Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual α2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties
por: Canale, Vittorio, et al.
Publicado: (2021)

A Comparison of the Anorectic Effect and Safety of the Alpha(2)-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity
por: Dudek, Magdalena, et al.
Publicado: (2015)

MH-76, a Novel Non-Quinazoline α(1)-Adrenoceptor Antagonist, but Not Prazosin Reduces Inflammation and Improves Insulin Signaling in Adipose Tissue of Fructose-Fed Rats
por: Kubacka, Monika, et al.
Publicado: (2021)

The Structural Determinants for α(1)-Adrenergic/Serotonin Receptors Activity among Phenylpiperazine-Hydantoin Derivatives
por: Kucwaj-Brysz, Katarzyna, et al.
Publicado: (2021)

Metabolic and cardiovascular benefits and risks of 4-hydroxy guanabenz hydrochloride: α(2)-adrenoceptor and trace amine-associated receptor 1 ligand
por: Kotańska, Magdalena, et al.
Publicado: (2023)

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia
por: Marcinkowska, Monika, et al.
Publicado: (2021)

Chemically Homogenous Compounds with Antagonistic Properties at All α(1)-Adrenoceptor Subtypes but not β(1)-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats
por: Pytka, Karolina, et al.
Publicado: (2016)

Manifestations of Liver Impairment and the Effects of MH-76, a Non-Quinazoline α1-Adrenoceptor Antagonist, and Prazosin on Liver Tissue in Fructose-Induced Metabolic Syndrome
por: Kubacka, Monika, et al.
Publicado: (2023)

Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides
por: Borhade, Sanjay R, et al.
Publicado: (2014)

The Antiarrhythmic and Hypotensive Effects of S-61 and S-73, the Pyrrolidin-2-one Derivatives with α(1)-Adrenolytic Properties
por: Lustyk, Klaudia, et al.
Publicado: (2022)

Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents
por: Marcinkowska, Monika, et al.
Publicado: (2018)

HBK-10, A Compound with α(1)-Adrenolytic Properties, Showed Antiarrhythmic and Hypotensive Effects in Rats
por: Lustyk, Klaudia, et al.
Publicado: (2022)

Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide
por: Santamaria, Salvatore, et al.
Publicado: (2021)

Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors
por: Cuffaro, Doretta, et al.
Publicado: (2021)

Evaluation of Some Safety Parameters of Dual Histamine H(3) and Sigma-2 Receptor Ligands with Anti-Obesity Potential
por: Mika, Kamil, et al.
Publicado: (2023)

KD-64—A new selective A(2A) adenosine receptor antagonist has anti-inflammatory activity but contrary to the non-selective antagonist—Caffeine does not reduce diet-induced obesity in mice
por: Kotańska, Magdalena, et al.
Publicado: (2020)

QSPR analysis of some agonists and antagonists of α-adrenergic receptors
por: Kawczak, Piotr, et al.
Publicado: (2014)

Novel Arylpiperazine Derivatives of Salicylamide with α(1)-Adrenolytic Properties Showed Antiarrhythmic and Hypotensive Properties in Rats
por: Żmudzka, Elżbieta, et al.
Publicado: (2022)

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
por: Roehrborn, Claus G., et al.
Publicado: (2016)

In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics
por: Jamrozik, Marek, et al.
Publicado: (2023)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas’ Disease
por: Lima, Marta L., et al.
Publicado: (2022)

Design, Synthesis, and Cytotoxic Activity of Novel Natural Arylsulfonamide-Inspired Molecules
por: Huang, Wenbo, et al.
Publicado: (2022)

Evaluation of the In Vitro Antifungal Activity of Novel Arylsulfonamides against Candida spp.
por: Ginestra, Giovanna, et al.
Publicado: (2023)

A Suspected Case of Silodosin-Induced Erythroderma
por: Liu, Annie, et al.
Publicado: (2015)

Silodosin-associated intraoperative floppy iris syndrome
por: Chatterjee, Samrat, et al.
Publicado: (2017)

Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist
por: Kotańska, Magdalena, et al.
Publicado: (2017)

Guanabenz—an old drug with a potential to decrease obesity
por: Kotańska, Magdalena, et al.
Publicado: (2022)

1-(Arylsulfonyl-isoindol-2-yl)piperazines as 5-HT(6)R Antagonists: Mechanochemical Synthesis, In Vitro Pharmacological Properties and Glioprotective Activity
por: Canale, Vittorio, et al.
Publicado: (2022)

Clinically Meaningful Improvements in LUTS/BPH Severity in Men Treated with Silodosin Plus Hexanic Extract of Serenoa Repens or Silodosin Alone
por: Boeri, Luca, et al.
Publicado: (2017)

Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial
por: Rahman, Md Jawaid, et al.
Publicado: (2017)

A third generation of radical fluorinating agents based on N-fluoro-N-arylsulfonamides
por: Meyer, Daniel, et al.
Publicado: (2018)

Novel Donepezil–Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer’s Disease
por: Queda, Fausto, et al.
Publicado: (2021)

In Silico Design, Synthesis, and Biological Evaluation of Anticancer Arylsulfonamide Endowed with Anti-Telomerase Activity
por: Culletta, Giulia, et al.
Publicado: (2022)

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011)

Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
por: Sakata, Koichi, et al.
Publicado: (2012)

Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT(1A) receptor partial agonists
por: Partyka, Anna, et al.
Publicado: (2020)

Suppression of osteoclastogenesis via α2-adrenergic receptors
por: Hamajima, Kosuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o6i4i41j4rrjjllksfkn2m7h6j